Results 301 to 310 of about 5,698,803 (355)

Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active

Arthritis Care &Research, EarlyView.
Objective This study aimed to identify in patients with systemic lupus erythematosus (SLE) with clinically active disease the attainment of frequency and determinants of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) and the frequency and determinants of flare and damage accrual after target attainment.
Yanjie Hao, Dylan Hansen, Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Yi‐Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue Fen Luo, Yeong‐Jian Jan Wu, Sandra Navarra, Leonid Zamora, Zhanguo Li, Sargunan Sockalingam, Yasuhiro Katsumata, Masayoshi Harigai, Zhuoli Zhang, Madelynn Chan, Jun Kikuchi, Tsutomu Takeuchi, Sang‐Cheol Bae, Fiona Goldblatt, Sean O'Neill, Kristine (Pek Ling) Ng, Annie Law, B. M. D. B. Basnayake, Nicola Tugnet, Sunil Kumar, Cherica Tee, Michael Tee, Naoaki Ohkubo, Yoshiya Tanaka, Shirley Chan, C. S. Lau, Vera Golder, Alberta Hoi, Shereen Oon, Eric Morand, Mandana Nikpour, for the Asia‐Pacific Lupus Collaboration   +39 more
wiley   +1 more source

Identification and Characterization of eccDNA in HepG2 Cells Under DOX-Induced DNA Damage. [PDF]

Int J Mol Sci
Zhang J, Li Y, Chen W, Du X, Zheng J, Chen J, Huang X, Pang C, Guo Z.   +8 more
europepmc   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Arthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H. Weisman, Philip M. Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, David Wofsy, Diane Kamen, Richard A. Furie, Deepak A. Rao, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Chun‐Hao Lee, Derek Fine, Manny Monroy‐Trujillo, Ummara Shah, Mariko Ishimori, Robert M. Clancy, Michael Belmont, Ming Wu, Nicole Bornkamp, Evan Der, Beatrice Goilav, Nicole Jordan, Daniel Schwartz, James Pullman, David Wofsy, Dawn Smilek, Patti Tosta, Matthias Kretzler, Celine C. Berthier, E. Steve Woodle, Dave Hildeman, Michael Brenner, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +48 more
wiley   +1 more source

Elevated DNA damage without signs of aging in the short-sleeping Mexican cavefish. [PDF]

Elife
Lloyd E, Xia F, Moore K, Zertuche Mery C, Rastogi A, Kozol RA, Kenzor O, Warren W, Appelbaum L, Moran RL, Zhao C, Duboue ER, Rohner N, Keene AC.   +13 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

RBM39 Contributes to MGMT Maintenance in Response to Temozolomide-Induced DNA Damage. [PDF]

Cancers (Basel)
Khalaj V, Adams JT, AghaAmiri S, Hernandez Vargas S, Bateman TM, Ghosh SC, Momeny M, Azhdarinia A.   +7 more
europepmc   +1 more source

Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

Arthritis Care &Research, Accepted Article.
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi, Andrea Fava, Daniel W Goldman, Laurence S Magder, Michelle Petri   +4 more
wiley   +1 more source

Oxidative stress triggers RNAPII arrest through PARylation and DNA damage

Thomas QA, Wu L, Lesage E, Iversen HKM, López Martínez D, Kompocholi S, Liu H, Nieto Moreno N, Gregersen LH.   +8 more
europepmc   +1 more source

Clove Essential Oil Enhances Antioxidant Defenses and Reduces DNA Damage in a Cellular Model of Parkinson's Disease. [PDF]

Parkinsons Dis
Hamdi D, Ouachik O, Kocer A, Ouchchane L, Messaoud C, Hafidi A.   +5 more
europepmc   +1 more source